CD24Fc (GVHD prevention in MPN transplant)
Current understanding
To be populated as evidence accumulates.
Evidence log
- Foundation — FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases: FDA Orphan Products Grants Program awarded OncImmune $2M to advance CD24Fc for GVHD prevention in MPN transplant patients; no clinical efficacy or safety data yet reported (funding announcement). (novelty: 3)
Open questions
Related
Contributing findings
FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases
Foundation announcement (recent)
novelty 3
per-area 4
introduces